Objective-Vascular fusion represents an important mechanism of vessel enlargement during development; however, its significance in postnatal vessel enlargement is still unknown. During fusion, 2 adjoining vessels merge to share 1 larger lumen. The aim of this research was to identify the molecular mechanism responsible for vascular fusion. Approach and Results-We previously showed that both low shear stress and DAPT (N-[N-(3,5-difluorophenacetyl
V ascular remodeling is an essential stage of vascular development; embryos that fail to remodel die between embryonic days 9.5 and 10.5 in mice.
1,2 During remodeling, blood vessels enlarge. We, 3 and others, 4 have observed that enlargement occurs by a process called vascular fusion. During fusion, the avascular region between 2 vessels reduces in size, bringing 2 neighboring small-caliber vessels into close proximity. As these vessels come into contact, the endothelial cells rearrange their cell-cell junctions to form 1 vessel with a single, common lumen (for review, see ref 5 ).
See accompanying editorial on page 1959
Although fusion is a normal process during vessel enlargement, when the molecular signaling pathways governing this process are aberrant, a hyperfused plexus arises. 3 For instance, hyperfused vascular plexuses have been observed in the yolk sacs of mice with Notch signaling mutations, such as nonviable δ-like 4 heterozygous embryos (nonviable Delta-like 4 +/− ) 6 and embryos expressing an endothelial-specific dominant negative form of mastermind-like (tyrosine kinase with immunoglobulin-like and epidermal growth factor-like domains 2-Cre+;dominant negative form of mastermind-like). 7 We have recently reported on the hyperfused vascular plexus in the yolk sac of a developing mouse embryo treated with the γ-secretase inhibitor DAPT (N-[N- (3,5-difluorophenacetyl 
)-L-alanyl]-S-phenylglycine t-butyl ester).
In the same work, we showed that similar to DAPT treatment, reduced levels of shear stress, a force generated by blood flow, cause increased rates of blood vessel fusion. 3 Both low shear stress 8 and DAPT treatment 9 have been reported to affect phosphorylation of vascular endothelialcadherin (VEC), an adherens junction protein involved in the integrity of intercellular junctions. Moreover, embryos lacking vascular endothelial-protein tyrosine phosphatase (VE-PTP), a phosphatase that dephosphorylates VEC, die at embryonic day 9.5, exhibiting an exceedingly hyperfused plexus. 10 These observations prompted us to hypothesize that vascular fusion requires VEC phosphorylation.
In this study, we investigate the common molecular mechanisms responsible for pathological vascular fusion downstream of DAPT treatment and decreased shear stress. We found that in yolk sacs of mouse embryos treated with DAPT or subject to reduced shear stress, fusing regions were positive for phosphorylated VEC staining. Interestingly, increasing levels of shear stress were able to counteract and rescue the hyperfused phenotype caused by DAPT treatment. In support of a VEC role in this process, we showed that increased VEC phosphorylation after DAPT treatment was prevented by higher levels of shear stress. High shear stress promoted the association of VEC with its phosphatase VE-PTP. Furthermore, we showed that the inhibition of Src (protooncogene tyrosine-protein kinase Src), an established mediator of VEC phosphorylation, rescued hyperfusion induced by either low shear stress or DAPT treatment. Last, we found that cell membrane localization of VEC downstream motor protein moesin was increased during the process of hyperfusion.
Materials and Methods
Data available upon request from the authors.
Reagents and Antibodies
Reagents and antibodies include as follows: DAPT (Sigma, D5942), 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo [3,4-d] pyrimidine (PP2; Sigma, P0042), 4-amino-7-phenylpyrazolo [3,4-d] pyrimidine (PP3; Cayman Chemical, 15595), cluster of differentiation 31 (CD31) biotinylated rat anti-mouse (BD Bioscience, 553371), VEC goat anti-mouse (R&D, AF1002), VEC goat anti-human (Santa Cruz, SC-6458), pY685 VEC rabbit anti-human (pVEC, ECM Bioscience, CP1981), VE-PTP rabbit anti-human (SC-28905, Santa Cruz), pY416 Src rabbit anti-human (Cell Signaling, 6943), Src rabbit anti-human (Cell Signaling, 2109), Cleaved Notch (Val1744; D3B8) rabbit monoclonal (Cell Signaling Technology no. 4147), GAPDH mouse anti-human (Fitzgerald, 10R-G109b), moesin rabbit anti-human (Abcam, ab52490), myosin heavy chain II rabbit antihuman (Eurogentec, PRB-440P-050). All secondaries for immunofluorescence were AlexaFluor labeled (ThermoFisher Scientific).
Embryos Isolation and Culture
All animal studies were approved by the Animal Welfare Committee of KU Leuven. Embryos were collected early on the morning of the eighth day of gestation (embryonic day 8.0 or ≈4-5 somite pairs) in warmed media under a temperature-controlled hood at 37°C, as described previous. 11 To reduce shear stress levels in vivo, we used a technique that we have previously developed, 2 which prevents the erythroblasts from leaving the blood islands and entering into circulation. After dissection, a solution of 15% acrylimide/bis-acrylimide with 10 mmol/L ammonium persulfate dissolved in PBS was injected directly into the blood islands of the embryonic yolk sac. The blood islands were then injected a second time with 50% tetramethylethyleendiamine 50% PBS to catalyze the polymerization. To increase shear stress, embryos were cultured for 2 hours and then injected with a 6% hetastarch solution directly into the yolk sac blood vessels. This solution makes the blood plasma more viscous. To normalize shear stress levels, the blood islands were first immobilized, and embryos were cultured for 2 hours. Embryos were then injected with 6% hetastarch solution and cultured for a further 4 hours. This represents the stage where erythroblasts normally enter circulation.
Flow ablation was achieved by snipping the vessels leading into the heart of embryonic day 8.5 embryos. Embryos were cultured for 2 hours, at which point the surgical wound has healed; however, the scar tissue leads to nonlumenized vessels. The lack of circulating erythroblasts was assessed after culture, and only embryos lacking circulating erythroblasts were kept for analysis.
For the inhibitor treatment, embryos were cultured for 2 hours and then DAPT and PP2 (50 µmol/L) or DAPT and PP3 (50 μmol/L) were added to the culture medium. The embryos were returned to the tissue culture incubator for an additional 2, 4, or 24 hours. The inhibitors were added only once to the culture media.
Embryo Staining and Quantification
After culture, embryos were fixed in Dents' solution overnight. Embryos were permeabilized with Tris-NaCl-Tween buffer for 30 minutes and then blocked with Tris-NaCl-Blocking reagent buffer for 1 hour at room temperature. Embryos were incubated overnight with primary antibody and then washed 5×1 hour in Tris-NaCl-Tween buffer, followed by overnight incubation with secondary antibody and subsequent 5×1 hour washes. For pVEC, Superboost Amplification (Invitrogen, B40926) was used according to manufacturer's instructions. Quantification of the phenotype was performed on 3 fields per yolk sac, 4 to 6 embryos per group.
The specificity of the pY685 VEC antibody was tested by performing immunofluorescent staining on knock-in mouse embryo containing VEC point mutation Y685F or wild-type VEC (previously described in ref 12 ). As shown in Figure I in the online-only Data Supplement, knock-in VEC wild-type embryo showed specific pVEC (red) staining that colocalized with total VEC (green). Background pVEC staining observed in VEC-Y685F knock-in mouse; however, this staining was nonspecific and diffuse, and it did not overlap with the staining for total VEC ( Figure I in the online-only Data Supplement).
The images were processed and analyzed by ImageJ. All analysis was performed with ImageJ Angiogenesis Analyzer. This tool allows detailed quantification of several vasculature structures, such as number of junctions, segments, meshes, or loops. The percentage of CD31-positive areas was evaluated to determine vascular density. For area calculations, the images were quantified by ImageJ Area Fraction analysis.
Cell Culture and Shear Stress Experiments
Human cardiac microvascular endothelial cells (Lonza, CC-2927) were cultured in endothelial growth medium 2MV (EGM-2MV, CC-3162) according to manufacturer's protocol. Endothelial cells were seeded on glass slides (VWR, MENZJ5800AMNZ) coated with collagen I (ThermoFisher Scientific, A-10483-01). Sixteen hours before performing the experiment, cells were cultured with starvation medium consisting of EGM-2MV but only 0.5% fetal bovine serum and without vascular endothelial growth factor (VEGF) A 165 and basic fibroblast growth factor. The slide was placed in a parallel plate flow chamber, and flow of starvation media was driven using a peristaltic pump. For inhibitor treatment, 10 μmol/L DAPT and 20 μmol/L PP2 were added to starvation media.
Immunoblotting and Immunoprecipitation
Proteins were isolated in radioimmunoprecipitation buffer (Sigma Aldrich, sc-24948). Samples were heated at 95°C for 5 minutes in SDS-PAGE sample buffer, loaded on a 5% or 7% polyacrylamide gel, and were subjected to electrophoresis. Proteins were transferred to a nitrocellulose membrane (VWR, RPN2235) for 30 minutes using Trans-Blot Turbo Transfer System (Biorad). Membranes were blocked with 5% BSA in Tris-buffered saline with Tween for 1 hour. The membranes were exposed to primary antibodies and subsequently incubated with appropriate horseradish peroxidase-labeled secondary antibody. The detection was performed by using SuperSignal West Nonstandard Abbreviations and Acronyms
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Femto or Pico substrate (Pierce, 34095 and 34077, respectively) and was visualized with a ChemiDoc XRS System (BioRad). For coimmunoprecipitations, cells were fixed in 1% paraformaldehyde for 5 minutes and lysed in lysis buffer IGEPAL (Sigma, CA-630). Lysates were centrifuged at 4°C for 10 minutes at 3400g, one aliquot was set aside for direct blot analysis, and the rest was incubated with 1 μg of VE-PTP antibody at 4°C overnight. Lysates were then incubated with Dynabeads Protein G (ThermoFisher Scientific, 10003D) for 4 hours at 4°C. Immuno-complexes were washed 3× with lysis buffer and analyzed by Western blot.
For quantification, TIFF images of the Western blots obtained with Image Lab software were imported in ImageJ. A defined region was selected containing the band of interest. The rectangular areas defining the Western bands were set on each lane to obtain the peaks representing the relative density of the contents by clicking gels, label peak under the Analyze menu. A line across the base of the peak was drawn to enclose the peak. Each peak was labeled and expressed as a percentage of the total size of all of the highlighted peaks. The values, that appeared in results window, were copied to an excel spreadsheet for further analysis.
Statistical Analysis
Statistical significance was determined by applying 1-way ANOVA tests followed by Tukey post hoc test, if significance was found (SigmaStat Software, San Jose).
Results

Increased VEC Phosphorylation Is Present in Models of Increased Vascular Fusion
Two models of hyperfusion were used in this study: a mechanical model, where erythroblasts were immobilized in the blood islands, resulting in vascular development occurring in the presence of plasma flow rather than whole blood flow such that the level of shear stress is lower 2 ; and a molecular model where embryos were cultured in the presence of the γ-secretase inhibitor DAPT. After culture, vessels were visualized with staining for CD31 ( Figure II in the online-only Data Supplement). To investigate the role of VEC in vascular fusion, we stained the yolk sac vasculature of these embryos with an antibody against CD31 ( Figure 1A , green), total VEC ( Figure 1A , red), and phosphorylated VEC ( Figure 1A , white). We found that hyperfused blood vessels were positive for VEC phosphorylation in mouse embryos treated with DAPT or after erythroblast immobilization. In comparison, little VEC phosphorylation was present in control embryos ( Figure 1A ).
When we expose embryos to DAPT treatment, it is possible that their heart function is affected, therefore creating low shear stress similar to immobilization. To ensure that the defects in DAPT-treated embryos were not secondary to flow defects, we verified the presence of strong circulation of erythroblasts after culture. We further confirmed that DAPT induces a hyperfused phenotype independent of flow by completely ablating blood flow, using a technique we previously developed. 13 Treatment with DAPT resulted in hyperfusion whether flow was present or not ( Figure III in the online-only Data Supplement). Furthermore, complete ablation of flow in the absence of DAPT did not induce hyperfusion ( Figure III in the online-only Data Supplement). Embryos lacking flow do not remodel, but they also do not hyperfuse. These results indicate that low shear stress specifically, but not flow arrest, induces hyperfusion in the mechanical model.
In vitro, both DAPT treatment and low shear stress induced VEC phosphorylation. Endothelial cells treated with DAPT showed increased VEC phosphorylation, which reached a peak after 4 hours of treatment ( Figure 1B ). Similar to DAPT treatment, exposure of endothelial cells to low shear stress (1.8 dynes/cm 2 ) for 4 hours increased VEC phosphorylation as compared with cells cultured under static condition. Under higher levels of shear stress (3.5 and 10 dynes/cm 2 ), VEC phosphorylation returned to levels comparable to static control ( Figure 1C ). These data establish that VEC phosphorylation is a common target of low shear stress and DAPT treatment during blood vessel remodeling.
Our in vitro results show that the peak of VEC phosphorylation occurs after 4 hours of DAPT treatment ( Figure 1B) . To establish exactly when hyperfusion begins in vivo, we performed a time series analysis of embryos cultured with DAPT ( Figure IV in the online-only Data Supplement) and quantified the avascular loops and percentage of vascular area. Fusion results in an increase in the percentage of the area that is positive for the endothelial marker CD31, a decrease in the number of avascular loops, and an increase in the average segment length. In agreement with our in vitro results, we first detected hyperfusion in embryos after 4 hours of culture with DAPT ( Figure IV in the online-only Data Supplement). We used this time point for all future experiments.
Besides the remodeling of the extraembryonic vasculature, the dorsal aorta also undergoes to 2 different fusion events during embryonic development. For a short time, as the dorsal aorta is forming at ≈3 somites, the vasculature of the dorsal aorta is a plexus. Charles Little and Christopher Drake 5, 14 have published time-lapses showing this in chick embryos and also showed that this plexus becomes a single vessel by vascular fusion. Another fusion event in the embryo occurs later in dorsal aorta development. The dorsal aorta consists initially of 2 bilateral vessels, which fuse into 1 single aorta at embryonic day 9.25 (14 somites). We have performed pVEC staining of the dorsal aorta at both stages. During the early formation stages (embryonic day 8.0, 3-4 somites), we found that the dorsal aorta stains positive for pVEC. At later stages (E9.25), we did not see any pVEC positive staining ( Figure  V in the online-only Data Supplement). Chordin and BMP4 (bone morphogenetic protein 4) signaling have been shown to be required for the fusion event at 14 somites. VEGF and Shh signaling are also involved but do not drive the process. 15 Therefore, we think that this event may be a different type of fusion or at least have different signals that initiate the process.
Increased Shear Stress Counteracts Vascular Fusion by Inducing VEC/VE-PTP Interaction and Thereby Preventing VEC Phosphorylation
We previously showed that increasing shear stress levels in the embryo, achieved by injecting hetastarch intravascularly to increase blood plasma viscosity, partially rescued fusion induced either by DAPT or by erythroblast immobilization in embryos cultured for 16 hours. 3 In line with our previous results, increasing shear stress via hetastarch injection completely rescued the fusion phenotype in both erythroblast immobilization and by DAPT treatment when cultured for 4 hours (Figure 2A and 2B) . To investigate whether the ability of increased shear stress to 2 ) induces phosphorylation of VEC as compared with static conditions. Shear stress levels of 3.5 and 10 dynes/cm 2 reduce pY685VEC to levels similar to control cells.
rescue the hyperfused phenotypes correlates with changes in VEC phosphorylation, we exposed endothelial cells in culture to different levels of shear stress, in the presence or absence of DAPT. We found that increased shear stress suppresses VEC phosphorylation induced by DAPT treatment ( Figure 2C ). The γ-secretase complex inhibitor, DAPT, is most often referred to as a Notch inhibitor because it prevents the second proteolytic cleavage of Notch receptor. We, therefore, investigated whether the effect of DAPT on VEC phosphorylation was because of Notch inhibition, by performing Western blots for the Notch-intercellular-domain. However, under serumstarved conditions, we find no significant Notch activation in any of the conditions tested ( Figure VI in the online-only Data Supplement). Besides Notch, γ-secretase complex, is also known to cleave other proteins, that is, N-and E-cadherin. 16, 17 It is thus possible that the addition of DAPT induces VEC phosphorylation and vascular fusion by directly interfering with molecular mechanisms regulating cell-cell adhesion independently of Notch.
In endothelial cells, phosphorylated VEC can be dephosphorylated by the phosphatase VE-PTP. 18 Indeed, VE-PTP and VEC are thought to physically interact through their extracellular domains to dynamically maintain endothelial barriers. 18, 19 We investigated how different levels of shear stress affect VEC interaction with VE-PTP. We found that the amount of VEC that coimmunoprecipitated with VE-PTP was significantly higher in cells subjected to physiological shear stress (10 dynes/cm 2 ) as compared with cells exposed to low shear stress (1.8 dynes/cm 2 ) or cultured under static condition ( Figure 3A ). In addition, we find that while VE-PTP is primarily localized in the perinuclear region in cells exposed to static or low shear stress, it relocated to the plasma membrane when cells were subjected to higher shear stress and was therefore in closer proximity to VEC ( Figure 3B , yellow arrows). These observations are in agreement with a recent study showing that VE-PTP redistributes in a polarized way in endothelial cells according to the direction of flow in a time-and shear stress level-dependent manner. 20 
Inhibition of Src Prevents VEC Phosphorylation and Vascular Fusion
Src-family kinases are necessary for VEC phosphorylation in response to VEGF or low shear stress. 8, 21 To test whether Src also plays a role in VEC phosphorylation in response to DAPT treatment and low shear stress, we exposed endothelial cells to DAPT or 1.8 dynes/cm 2 shear stress in the presence or absence of the Src kinase inhibitor PP2. We found that PP2 treatment prevented VEC phosphorylation stimulated by DAPT or low shear stress ( Figure 4A ). Inhibition of Src activity was validated after PP2 administration by Western blot for phosphorylated Src ( Figure 4B ). We used the ability of PP2 to prevent VEC phosphorylation to investigate whether phosphorylation of VEC was necessary for fusion in vivo. We cultured embryos with DAPT or with erythroblast immobilization in presence or absence of PP2. PP2 was able to prevent vascular fusion triggered by DAPT treatment or erythroblast immobilization ( Figure 4C and 4D) . Conversely, the addition of PP3, a negative control for the inhibitor PP2, was unable to prevent fusion after DAPT treatment or erythroblast immobilization ( Figure VII in the online-only Data Supplement). These data indicate that the inhibition of the phosphorylation and activation of Src-family members, responsible for VEC phosphorylation, rescue hyperfusion in vivo. 
Molecular Motors Downstream of VEC Phosphorylation Are Activated During Hyperfusion
During lumen formation in the mouse embryo, moesin and NMM2 (non-muscle myosin II) are activated in a VECdependent manner. 22 Moesin and NMM2 activation induces adjacent endothelial cells to pull away from each other thereby forming the lumen. Although the work by Strilic et al 22 focused on lumenization, lumen formation is a process that often takes place during branching and vascular fusion. It is thus possible that these biological processes share molecular mechanisms. We, therefore, investigated whether an increase in membranelocalized moesin or NMM2 occurred in embryos undergoing hyperfusion using immunostaining. In control embryos, moesin shows a diffuse endothelial cell-specific staining pattern ( Figure 5A ). In both our models of hyperfusion, DAPT treatment, and erythroblast immobilization, moesin is concentrated at the cell membrane resulting in an overall increase in the number of fluorescent pixels above threshold ( Figure 5B ). In contrast, NMM2 staining showed no significant differences between control and treated embryos ( Figure 5C and 5D ).
Discussion
Fusion of 2 blood vessels is a physiological process that occurs frequently during the formation of large vessels in the embryo. 4, 5, 23 However, when the molecular signaling pathways or hemodynamic stimuli involved in vascular fusion are disturbed, the vascular network becomes hyperfused. In support of this, we have previously shown that DAPT treatment or erythroblast immobilization results in hyperfusion of the vasculature in the mouse embryo yolk sac. 3 The observation that reduced shear stress and DAPT treatment both result in a hyperfused yolk sac vascular network strongly indicates that these treatments regulate common molecular targets responsible for vascular fusion. Here, we show that VEC phosphorylation correlates with the process of vascular fusion. On the basis of our findings, we propose a model in which low shear stress and DAPT treatment both result in the activation of a Src-family kinase which phosphorylates VEC, initiating the process of vascular fusion. Conversely, increased shear stress induces the physical interaction of VE-PTP with VEC on the endothelial membrane, resulting in VEC dephosphorylation by VE-PTP, reducing vascular fusion.
The work of Orsenigo et al 8 on VEC phosphorylation and hemodynamic forces found that both tyrosine 685 and 658 were phosphorylated by low shear stress. We found the same (data not shown) and therefore used tyrosine 685 as an indicator of phosphorylation status of VEC in all our experiments. However, we also found that single point mutation Y685F of VEC knock-in mouse is not sufficient to prevent fusion induced by DAPT and low shear stress (data not shown). More recently, the tyrosine at position 658 has been shown to be flow responsive. 24 Thus, it is possible that the phosphorylation of VEC, on either Y658 alone, or on both Y685 and Y685, is needed for the process of vascular fusion to occur. Because of the fact that Y685F mutants can still hyperfuse, we conclude that VEC phosphorylation at Y685 alone is not sufficient to drive the fusion process.
Previous studies have reported that shear stress activates Notch cleavage [25] [26] [27] ; however, little work has been done at low shear stress level. Under our starvation conditions, we see a low level of activated Notch-intercellular-domain, such that DAPT could not further reduce the levels ( Figure IV in the online-only Data Supplement). Therefore, we exclude that in endothelial cells, the inhibition of canonical Notch signaling is responsible for VEC phosphorylation after DAPT treatment. Recently, Notch signaling induced by shear stress was shown to regulate vascular barrier function through the Notchtransmembrane-domain and independently from the Notchintracellular-domain. 27 It seems that high shear stress triggers DLL4 (Delta-like 4)-dependent proteolytic activation of Notch1, resulting in the exposure of the Notch-transmembranedomain which is sufficient to interact with VEC for the establishment of the vascular barrier. 27 Thus, it is possible that our results are transmembrane domain dependent, without release of the intracellular domain, or else, that our results arise from other functions of γ-secretases. A better understanding of the downstream mechanism, especially with respect to moesin, could help to differentiate these possibilities.
Hyperfused plexuses have been observed in several embryonic knockout mouse models as mentioned above. 6, 7, 10 At least one potential loss-of-function phenotype has also been reported. 28 In Sema3E-deficient embryos, the dorsal aorta exists as a plexus at 7 somites, rather than the large paired aortas that are present in wild-type embryos. The phenotype is resolved at the stage when blood flow starts in the embryo, 2, 28 and the process of resolution seems to occur by fusion although the resolution of the phenotype was observed in still images rather than time-lapse microscopy. Thus, it is impossible to be certain that this involved fusion. The plexinD1-null embryos showed similar vascular defects.
28 Sema3E-plexinD1 signaling has been shown to negatively regulate DLL4-induced Notch signaling. 29 As such, it is possible that lack of sema3E or plexinD1 prevents fusion as a result of increased DLL4 which induces Notch signaling because of the exposure of Notch-transmembrane-domain as described above.
The Notch signaling pathway has been extensively studied in models of sprouting angiogenesis. Several studies have shown in different systems, including mouse retina and hindbrain, 30 zebrafish embryos, 31 and tumors, 32 that the Notch signaling pathway acts as a negative regulator of angiogenesis by limiting vascular sprouting. However, the effects of Notch are context dependent. Pathologically high levels of VEGF induce endothelial cell synchronization of Dll4/Notch signaling, leading to vessel enlargement rather than sprouting. 33 The vasculature in mouse embryos after the onset of flow has relatively few new sprouts forming, 3 indicating that VEGF concentrations are at levels that promote endothelial cell survival rather sprouting. In this context, Notch inhibition results in a hyperfused plexus rather than a hypersprouting plexus. This does not, however, exclude a possible role for sprouting in the process of vascular fusion. Previous work on vascular fusion has proposed that sprouting is an important step that precedes fusion and is necessary to reduce the size of avascular regions. 5 To understand how the process of vascular fusion is regulated downstream of phosphorylated VEC, we investigated whether motor proteins, such as moesin and NMM2, previously described to be VEC targets, were expressed in fusing vessels. We found that moesin, important for endothelial cell rearrangement, localizes at the cell membrane during hyperfusion. We cannot, however, rule out a role for permeability during this process. Indeed, fusion occurs in regions where large vessels are forming and as such the avascular regions between 2 fusing vessels are under low shear stress but high blood pressure. These regions will, therefore, also have increased interstitial flow. VEC phosphorylation increases permeability, which would also increase interstitial flow. It is possible that VEC phosphorylation is necessary to create a positive feedback loop that amplifies the increases in interstitial flow.
The noncanonical Notch signaling activated by shear stress was shown to induce assembly of a mechanosensory complex consisting of VEC, the transmembrane tyrosine phosphatase LAR (leukocyte common antigen-related protein), and the guanidine-exchange factor Trio. 27 Interestingly, in neurons, Trio regulates netrin which in turn regulates moesin during neuronal outgrowth, 34, 35 whereas no association with NMM2 and Trio has been reported to date. As such, the combination of the activation of moesin without NMM2 activation and the lack of association with patterns of cleaved Notchintercellular-domain would strongly suggest a role for noncanonical Notch signaling in the process of vascular fusion.
The stimuli that induce fusion in the embryo (ie, DAPT and low shear stress) do not cause the same hyperfused phenotype in the adult mouse. Thus, it is not clear whether fusion occurs post-natally. The extracellular matrix of blood vessels in the embryo contains a high proportion of fibronectin compared with adult vessels. 36, 37 Our in vitro results were likewise obtained on fibronectin. We found that low shear stress did not induce VEC phosphorylation in cells cultured on collagen (data not shown). Thus, differences between the embryo and the adult may be because of the composition of the extracellular matrix. The adult vasculature also has perivascular cell types, which have not yet differentiated in the embryo when remodeling is happening. Perivascular cells may represent a physical barrier preventing fusion post-natally. Ultimately, identifying the required factors for fusion to occur will help identify whether fusion is involved in pathophysiological remodeling post-natally.
The potential role of vascular fusion in pathology is completely unknown. We currently have no means to identify in vivo vascular fusion other than time-lapse microscopy. Vascular fusion temporarily results in small vascular pillars, but these structures are also present during intussusceptive angiogenesis. Pathologies can result in reactivation of developmental programs, and as such it is possible that fusion contributes to adult pathologies. Identifying whether fusion takes place requires an understanding of the molecular mechanism and the microenvironmental conditions necessary for the process to occur, allowing for the identification of a molecular signature for fusion post-natally.
In conclusion, this research provides the first evidence that VEC phosphorylation is present during vascular fusion. Gaining insights into mechanisms of vascular fusion will help develop therapeutic strategies not only to prevent defects during vascular development but also to fight vascular malformations in other contexts, such as cancer, macular degeneration, and atherosclerosis.
